Applied BioMath, LLC presenting at two international Systems Medicine conferences in Kiel, Germany

LINCOLN, Mass., Oct. 4, 2016 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced their participation in the Annual e:Med Meeting on Systems Medicine 2016 in Kiel, Germany on October 4-6, 2016.  Dr. John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath, will present a keynote presentation titled "Quantitative Modeling and Simulation Approaches: Providing Deep Biological Hypotheses and Driving Critical Decisions from Research through Clinical Trials for Inflammation and Immunology" on Tuesday October 4, 2016.  Dr. Lore Gruenbaum, PhD, Executive Director of Biology and Pharmacology, will participate in a panel discussing the direction of the future of medicine. 

Additionally, Dr. Gruenbaum will present on "Quantitative Systems Pharmacology: Applications in Drug Development" at the First International Symposium on Systems Medicine of Chronic Inflammatory Disorders (sysINFLAME) also being held in Kiel, Germany on October 6-7, 2016. 

"We have made significant advances incorporating quantitative modeling and simulation into immunology and oncology programs.  We are privileged to have been invited to share our work in these areas at the e:MED and sysINFLAME conferences."

Dr. John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath

About Applied BioMath

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, helps biotechnology and pharmaceutical companies answer complex, critical Go/No-go decisions in R&D.  Applied BioMath leverages biology, proprietary mathematical modeling and analysis technology, high-performance computing, and decades of industry experience to help groups better understand their candidate, its best-in-class parameters, competitive advantages, and the best path forward.  Our involvement shortens project timelines, lowers cost, and increases the likelihood of a best-in-class drug.  We provide clarity to complex situations, answer otherwise unanswerable questions, and our approach, when validated in the clinic, is 10x more accurate than traditional methodologies.

Applied BioMath and the Applied BioMath logo are trademarks of Applied BioMath, LLC.

Press contact:
Kristen Zannella
[email protected]

Logo - http://photos.prnewswire.com/prnh/20161004/414963LOGO

SOURCE Applied BioMath

Related Links

http://www.appliedbiomath.com